JP2023546453A5 - - Google Patents

Info

Publication number
JP2023546453A5
JP2023546453A5 JP2023524276A JP2023524276A JP2023546453A5 JP 2023546453 A5 JP2023546453 A5 JP 2023546453A5 JP 2023524276 A JP2023524276 A JP 2023524276A JP 2023524276 A JP2023524276 A JP 2023524276A JP 2023546453 A5 JP2023546453 A5 JP 2023546453A5
Authority
JP
Japan
Prior art keywords
substituted
pharmaceutically acceptable
solvate
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023524276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546453A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/000707 external-priority patent/WO2022084738A2/en
Publication of JP2023546453A publication Critical patent/JP2023546453A/ja
Publication of JP2023546453A5 publication Critical patent/JP2023546453A5/ja
Pending legal-status Critical Current

Links

JP2023524276A 2020-10-21 2021-10-20 眼障害を処置するための化合物および方法 Pending JP2023546453A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063094793P 2020-10-21 2020-10-21
US63/094,793 2020-10-21
US202163170988P 2021-04-05 2021-04-05
US63/170,988 2021-04-05
PCT/IB2021/000707 WO2022084738A2 (en) 2020-10-21 2021-10-20 Compounds and methods for the treatment of ocular disorders

Publications (2)

Publication Number Publication Date
JP2023546453A JP2023546453A (ja) 2023-11-02
JP2023546453A5 true JP2023546453A5 (cg-RX-API-DMAC10.html) 2024-10-29

Family

ID=81291739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023524276A Pending JP2023546453A (ja) 2020-10-21 2021-10-20 眼障害を処置するための化合物および方法

Country Status (8)

Country Link
EP (1) EP4232149A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023546453A (cg-RX-API-DMAC10.html)
KR (1) KR20230110515A (cg-RX-API-DMAC10.html)
AU (1) AU2021363702A1 (cg-RX-API-DMAC10.html)
CA (1) CA3196145A1 (cg-RX-API-DMAC10.html)
IL (1) IL302173A (cg-RX-API-DMAC10.html)
MX (1) MX2023004537A (cg-RX-API-DMAC10.html)
WO (1) WO2022084738A2 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212755A1 (en) 2019-04-18 2020-10-22 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
US11459351B1 (en) 2021-04-05 2022-10-04 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders
WO2024100454A2 (en) * 2022-11-11 2024-05-16 Azura Ophthalmics Ltd. Composition and methods for improving signs and symptoms of ocular disorders

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040005641A1 (en) * 2002-02-15 2004-01-08 Michael Burnet Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2013003731A2 (en) * 2011-06-29 2013-01-03 Insite Vision Incorporated Methods of treating recurrent meibomian glands disorder and thereby decreasing the frequency of recurrence
US11420995B2 (en) * 2017-03-03 2022-08-23 Synovo Gmbh Anti-infective and anti-inflammatory compounds
WO2018215638A1 (en) * 2017-05-26 2018-11-29 Novaliq Gmbh Pharmaceutical compositions comprising azithromycin
AU2020259997B2 (en) * 2019-04-18 2025-08-07 Azura Ophthalmics Ltd. Compounds and methods for the treatment of ocular disorders

Similar Documents

Publication Publication Date Title
JP2023546915A5 (cg-RX-API-DMAC10.html)
CY1122863T1 (el) Φαρμακευτικη συνθεση που περιεχει γλυκοπυρρολικο και εναν αγωνιστη βητα2 αδρενοϋποδοχεα
JP2008522981A5 (cg-RX-API-DMAC10.html)
JP2021152063A5 (cg-RX-API-DMAC10.html)
RU2002124522A (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
JP2023546452A5 (cg-RX-API-DMAC10.html)
KR927003624A (ko) 화합물
CA2504846A1 (en) Antiviral nucleoside derivatives
JP2018528261A5 (cg-RX-API-DMAC10.html)
DE69814012D1 (de) Hypoglykàmische imidazoline derivate
RU2006137706A (ru) 9-замещенное производное 8-оксоаденина
AR041273A1 (es) Compuestos de oxazol y tiazol como inhibidores del factor de crecimiento transformador (tgf)
JP2022529315A5 (cg-RX-API-DMAC10.html)
JP2019218546A (ja) ジアミン架橋剤、酸性多糖架橋体、及び医用材料
JP2025506206A (ja) がん治療のためのチオストレプトンから着想された化合物及びその調製
CA2491612A1 (en) 4-'7-halo-2-quino(xa-)linyloxy!phenoxy-propionic acid derivatives as antineoplastic agents
RU2015120074A (ru) Функционализированные производные 9-бром-камптотецина
RU2011108485A (ru) Новые (поли)аминоалкиламиноалкиламидные, алкилмочевинные или алкилсульфонамидные производные эпиподофиллотоксина, способ их получения и их применение в терапии в качестве противораковых средств
EP0463514B1 (en) 3.3'-Dithiobis (propionic acids) and esters thereof
JP2003511412A5 (cg-RX-API-DMAC10.html)
JP2005508910A5 (cg-RX-API-DMAC10.html)
JP2008174453A (ja) 頭皮脱毛治療剤
RU2014132830A (ru) Конъюгаты антагонистов интегрина для нацеленной доставки к клеткам, экспрессирующим vla-4
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
RU2005130992A (ru) Производные сложноэфирных липидов нуклеотидов